Clinical Trials Browser

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT07076550 2026-03-16

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Phase 1 Recruiting

50 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07364474 2026-03-11

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Phase NA Recruiting

10 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT04792463 2026-03-09

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Recruiting

500 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Cholangiocarcinoma

NCT06246149 2026-03-04

ATOM

Phase 3 Recruiting

290 enrolled

Dermatologic

Uveal Melanoma

NCT06007690 2026-03-02

CoMpass

Phase 3 Recruiting

100 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Phase 2 Recruiting

44 enrolled

Dermatologic

Uveal Melanoma

NCT06627244 2026-02-23

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Phase 2 Recruiting

30 enrolled

Dermatologic

Uveal Melanoma

NCT07421739 2026-02-19

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Recruiting

15 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

168 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Phase 1/2 Recruiting

200 enrolled

DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT06121180 2025-12-04

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Phase 2 Recruiting

32 enrolled

Dermatologic

Uveal Melanoma

NCT06940739 2025-12-03

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Phase 1/2 Recruiting

42 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1/2 Recruiting

109 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT07136181 2025-11-28

NBM-BMX-UM

Phase 1/2 Recruiting

36 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms, Neoplasm Metastasis, Recurrence

NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Phase 1 Recruiting

67 enrolled

DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04424719 2025-09-03

SALOME

Phase NA Recruiting

700 enrolled

Dermatologic

Uveal Melanoma

NCT07063875 2025-07-14

SILVER

Phase 1/2 Recruiting

8 enrolled

Dermatologic

Uveal Melanoma

Clinical Trials

DUET-MEL

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

ACTengine

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

TRIUMPH

Neoadjuvant Tebentafusp for Uveal Melanoma

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

IGCMU

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

ATOM

CoMpass

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

ON-5001

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Tebentafusp-tebn With LDT in Metastatic UM

NBM-BMX-UM

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

SALOME

SILVER